相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Relapsed classic Hodgkin lymphoma with decreased CD30 expression after brentuximab and anti-CD30 CAR-T therapies
Do Hwan Kim et al.
BLOOD (2022)
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb
Yang Wu et al.
CANCER GENE THERAPY (2022)
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma
S. Horwitz et al.
ANNALS OF ONCOLOGY (2022)
Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+Lymphoma
Wei Sang et al.
FRONTIERS IN IMMUNOLOGY (2022)
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jeffrey Ward et al.
BLOOD (2021)
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study
Martin Hutchings et al.
HEMATOLOGICAL ONCOLOGY (2021)
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla et al.
LANCET ONCOLOGY (2021)
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin's Lymphoma
YuanBo Xue et al.
FRONTIERS IN ONCOLOGY (2021)
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
Ranjana H. Advani et al.
BLOOD (2021)
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies
Lucila N. Kerbauy et al.
CLINICAL CANCER RESEARCH (2021)
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data
Steven M. Horwitz et al.
BLOOD ADVANCES (2021)
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
David J. Straus et al.
BLOOD (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach et al.
Lancet Haematology (2020)
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
Bruce D. Cheson et al.
LANCET HAEMATOLOGY (2020)
Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma
Jose D. Sandoval-Sus et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2019)
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
Pier Luigi Zinzani et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Activity of brentuximab vedotin in AIDS-related primary effusion lymphoma
Victoria A. Chang et al.
BLOOD ADVANCES (2019)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30
Louise E. Hogan et al.
PLOS PATHOGENS (2018)
Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
Craig H. Moskowitz et al.
BLOOD (2018)
Challenges of driving CD30-directed CAR-T cells to the clinic
Natalie S. Grover et al.
BMC CANCER (2018)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
Chun-Meng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Barbara Pro et al.
BLOOD (2017)
Classic and extracavitary primary effusion lymphoma in 51 HIV-infected patients from a single institution
Stephanie Guillet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding
Rami N. Al-Rohil et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2016)
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen et al.
BLOOD (2015)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Extensive toxic epidermal necrolysis following brentuximab vedotin administration
Maria Ilaria Del Principe et al.
ANNALS OF HEMATOLOGY (2015)
CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma
Shruti Bhatt et al.
BLOOD (2013)
Changing Incidence Trends of Cutaneous T-Cell Lymphoma
Kaveri Korgavkar et al.
JAMA DERMATOLOGY (2013)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage
G. Pizzolo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies in vitro and in vivo
Naoyoshi Maeda et al.
CANCER SCIENCE (2010)
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species
A. M. Vahdat et al.
LEUKEMIA (2010)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Madeleine Duvic et al.
CLINICAL CANCER RESEARCH (2009)
CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells
Burkhard Hirsch et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma
PB Staber et al.
LEUKEMIA RESEARCH (2006)
Lymphorna incidence patterns by WHO subtype in the United States, 1992-2001
LM Morton et al.
BLOOD (2006)
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
P Borchmann et al.
BLOOD (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
R Schnell et al.
ANNALS OF ONCOLOGY (2003)
Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study
C Simonelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Human CD30: Structural implications from epitope mapping and modeling studies
LY Dong et al.
JOURNAL OF MOLECULAR RECOGNITION (2003)
分享论文
